Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk

Executive Summary

Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21

You may also be interested in...



Biomarker Qualification Guidance To Require Fit For Use Validation

FDA's biomarker qualification guidance will establish a "fitness for use" standard for marker validation, Deputy Commissioner for Operations Janet Woodcock said

FDA To Provide Updates On Critical Path Opportunities List Projects

FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16

Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works

Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel